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Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder
associated with a premutation cytosine-guanine-guanine (CGG) trinucleotide repeat expansion of
the FMR1 gene. FXTAS is estimated to be the most common single-gene form of ataxia in the
aging population. Gait ataxia and intention tremor are the primary behavioral symptoms of FXTAS,
though clinical evaluation of these symptoms often is subjective, contributing to difficulties in reliably
differentiating individuals with FXTAS and asymptomatic premutation carriers. This study aimed to
clarify the extent to which quantitative measures of gait and upper limb kinematics may serve as
biobehavioral markers of FXTAS degeneration. Nineteen premutation carriers (aged 46–77 years),
including 9 with possible, probable, or definite FXTAS and 16 sex- and IQ-matched healthy controls,
completed tests of non-constrained walking and reaching while both standing (static reaching) and
walking (dynamic reaching) to quantify gait and upper limb control, respectively. For the non-
constrained walking task, participants wore reflective markers and walked at their preferred speed
on a walkway. During the static reaching task, participants reached and lifted boxes of different sizes
while standing. During the dynamic reaching task, participants walked to reach and lift the boxes.
Movement kinematics were examined in relation to clinical ratings of neuromotor impairments and
CGG repeat length. During non-constrained walking, individuals with FXTAS showed decreased
stride lengths and stride velocities, increased percentages of double support time, and increased
variabilities of cadence and center of mass relative to both asymptomatic premutation carriers and
controls. While individuals with FXTAS did not show any static reaching differences relative to
the other two groups, they showed multiple differences during dynamic reaching trials, including
reduced maximum reaching velocity, prolonged acceleration time, and jerkier movement of the
shoulder, elbow, and hand. Gait differences during non-constrained walking were associated with
more severe clinically rated posture and gait symptoms. Reduced maximum reaching velocity and
increased jerkiness during dynamic reaching were each related to more severe clinically rated kinetic
dysfunction and overall neuromotor symptoms in FMR1 premutation carriers. Our findings suggest
kinematic alterations consistent with gait ataxia and upper limb bradykinesia are each selectively
present in individuals with FXTAS, but not asymptomatic aging premutation carriers. Consistent with
neuropathological and magnetic resonance imaging (MRI) studies of FXTAS, these findings implicate
cerebellar and basal ganglia degeneration associated with neuromotor decline. Our results showing
associations between quantitative kinematic differences in FXTAS and clinical ratings suggest that
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objective assessments of gait and reaching behaviors may serve as critical and reliable targets for
detecting FXTAS risk and monitoring progression.
Keywords: FMR1 gene; fragile X−associated tremor/ataxia syndrome; gait; reaching; kinematics;
cerebellum; basal ganglia
1. Background
Fragile X-associated tremor/ataxia syndrome (FXTAS) is estimated to be the most
common single-gene form of ataxia in the aging population [1,2]. It is caused by premuta-
tion alleles consisting of 55–200 cytosine-guanine-guanine (CGG) trinucleotide repeats in
the 5′ untranslated region of the FMR1 gene [3,4]. Approximately 45% of male and 16% of
female FMR1 premutation carriers over 50 years develop FXTAS. The primary symptoms
include gait ataxia, intention tremor, and Parkinsonism, though symptom presentation
is variable across individuals, and some patients also show cognitive decline, psychiatric
issues, and autonomic dysfunction, among other comorbidities [1,2,5,6]. Multiple radi-
ological signs also inform diagnosis, including hyperintensities of the middle cerebellar
peduncle seen on T2-weighted magnetic resonance imaging (MRI), generalized cerebral
atrophy, and white matter hyperintensities of the splenium of the corpus callosum [1,2,7,8].
Due to the heterogeneous clinical and neuroanatomical presentations of FXTAS, the disease
mechanisms are not yet well understood. As such, many patients initially are misdiag-
nosed or diagnosed only after significant progression [9]. Objective approaches for reliably
identifying FXTAS are needed to advance our understanding of the disease mechanisms
and guide differential diagnosis and patient tracking.
Sensorimotor behaviors represent promising targets for clarifying mechanisms of
FXTAS and defining new biomarkers because (1) sensorimotor deficits are core defining
features of FXTAS [1,2]; (2) they are highly quantifiable in both the spatial (e.g., movement
amplitude) and temporal (e.g., movement duration, velocity, and acceleration) domains,
allowing precise characterization of subtle changes; and (3) they are supported by neocorti-
cal, striatal, and cerebellar brain networks implicated in both MRI and postmortem studies
of FXTAS [8,10,11].
Despite offering promise as targets for understanding disease mechanisms, sensori-
motor issues have been the subject of a relatively small number of quantitative studies
of FXTAS. Previous sensorimotor studies of FXTAS have demonstrated atypicalities in
precision manual motor control [12,13], postural control [14–16], and step initiation [8,13],
suggesting that multiple sensorimotor behaviors are compromised in carriers with FX-
TAS. More subtle sensorimotor issues also have been documented among asymptomatic
premutation carriers, including postural and precision manual control issues [12,14,17].
In particular, female carriers without FXTAS have shown subtle gross motor deficits (e.g.,
gait and step initiation) relative to asymptomatic male carriers during dual-task activities
that demand working memory processing [18,19]. These findings suggest that sensori-
motor deficits may manifest in aging FMR1 premutation carriers and differentially affect
females prior to the onset of FXTAS. Quantitative strategies to measure these subtle senso-
rimotor changes hold promise for identifying subclinical traits associated with aging in
premutation carriers prior to clinically observable disease symptoms. Quantitative studies
are needed to determine the extent to which different sensorimotor issues are specific to
FXTAS and which may develop early during aging in premutation carriers who are pre- or
asymptomatic.
Gait and upper limb movements may be especially important targets for understand-
ing FXTAS and establishing new disease-specific quantitative markers, because gait ataxia
and intention tremor are (1) major clinical signs of FXTAS [1,2], (2) included in standard
neurological evaluations of FXTAS [20], and (3) critical for adaptive daily living skills and
quality of life. During daily activities, lower limbs support postural stability and mobil-
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ity [21,22], while upper limb control is necessary for manipulating objects [23,24]. When
examined in combination, gait and reaching movements are planned in a coordinative and
compensatory manner [25]. Furthermore, the majority of daily living skills involve the
coordination of both lower and upper limb movement (e.g., carrying a glass of water from
one place to another). Both upper and lower limb deficits have been documented in studies
of aging FMR1 premutation carriers, but simultaneous analysis of upper and lower limb
movement features has not been done, and evaluating how they are related provides a
more ecologically valid assessment of the motor functions in premutation carriers and may
provide a more sensitive approach for detecting degeneration relative to the measurement
of either upper or lower limb movements in isolation.
Using the instrumented Timed Up and Go (i-TUG) test, O′Keefe et al. previously
indicated that individuals with FXTAS show a decreased stride amplitude, increased stride
variability, and prolonged transition between different movements relative to healthy con-
trols and age-matched premutation carriers without FXTAS [17]. Notably, gait issues also
were associated with age, cognitive decline, and increased CCG repeat length in carriers
with FXTAS [18,19,26,27], suggesting that quantitative gait assessment may be useful for
identifying FXTAS severity and risk. While the i-TUG test has provided valuable knowl-
edge about performance−based mobility, understanding is limited regarding locomotor
control in FMR1 premutation carriers with and without FXTAS during non-constrained
walking and activities involving the upper limbs. This knowledge gap is important because
non-constrained walking, assessed using a kinematic motion capture system, shows high
levels of test–retest reliability compared with performance-based gait tests, including the
i-TUG test, suggesting that it may be particularly useful for tracking disease progression
or prodromal degeneration [26]. Furthermore, lower limb-facilitated reaching, including
reaching-in-standing (i.e., static condition) and walking-for-reaching (i.e., dynamic condi-
tion), is critical for multiple daily activities (e.g., walking to pick up a glass from a dining
table), suggesting that they may relate strongly to functional abilities and their decline.
Kinematic studies of the gait and reaching behaviors may also provide important
insights into neural systems affected in FXTAS. For example, the cerebellum has been
repeatedly implicated in FXTAS, and studies of reaching in patients with cerebellar ataxia
have documented target overshooting [28,29], reduced coordination of multijoint move-
ments [30], and reduced end point accuracy [31,32]. Consistent with the hypothesis that
cerebellar degeneration plays a prominent role in sensorimotor issues associated with
FXTAS, we recently showed that increased variability of precision manual motor behav-
ior is associated with reduced functional connectivity between cerebellar Crus I and the
extrastriate cortex in aging premutation carriers [10]. To our knowledge, no studies have
simultaneously examined the gait and reaching in aging FMR1 premutation carriers with
and without FXTAS.
The current study had two objectives: (1) quantify disease-related behavioral pat-
terns by examining locomotor and upper limb kinematics during tasks of non-constrained
walking and arm reaching in healthy controls and premutation carriers with and without
FXTAS, and (2) determine the relationships of the gait and reaching kinematic variables
with disease risk factors, including age, CGG repeat length, cognitive ability (i.e., IQ),
and the neurological functions associated with FXTAS. For the first objective, we quantified
individuals’ non-constrained gaits across spatial, temporal, and kinematics dimensions,
as our group had previously identified deficits in these dimensions from other sensori-
motor activities in FMR1 premutation carriers [10,12–14]. Based on previous studies of
walking in FMR1 premutation carriers [17,26,27,33], we hypothesized that individuals
with FXTAS would show a reduced stride length, decreased stride velocity, and increased
percentage of double support time (i.e., percent of stride time spent with both feet in
contact with the ground), as well as increased variability of stride length and cadence
relative to healthy controls and asymptomatic carriers. As musculoskeletal weakness has
been consistently documented in individuals with FXTAS [1,34–37], we also predicted that
patients would show reduced knee flexion of the swing leg at toe-offs and reduced knee
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extension and ankle dorsiflexion of the ipsilateral leg at heel strikes. For tests of reaching,
we hypothesized that premutation carriers would show jerkier joint movement relative to
healthy controls, reflective of reduced multi-joint coordination that is often observed in
cerebellar patients [30,38–40]. We also examined reaching duration, maximum reaching
velocity, and acceleration time, as they represent common targets in studies of intention
tremor and Parkinsonism, two symptoms commonly seen in FXTAS. We also hypothesized
that reaching deficits would be more severe during dynamic trials of walking-for-reaching,
suggesting that gait impairments interrupt upper limb performance during goal-oriented
activities [25,41]. For the second objective, we hypothesized that increased abnormalities of
the gait and reaching kinematics in FMR1 premutation carriers would be associated with
increased age, CGG repeat length, and clinically rated movement issues, as well as lower
IQ scores, as they are all factors contributing to FXTAS risk, severity, and progression [1,2].
2. Materials and Methods
2.1. Participants
Nineteen FMR1 premutation carriers and 16 controls matched by age and sex were
enrolled in this study. FMR1 premutation carriers were identified through our fragile X
clinics and postings on local and national fragile X association listservs. Healthy controls
were recruited through community advertisements. Individuals were excluded if they
reported lower extremity orthopedic surgery within the past year, any musculoskeletal
disorder associated with an atypical gait, or a history of medications known to affect
sensorimotor functioning [42]. No individual reported any neurological concerns (e.g.,
postural and gait instability, tremor, or lack of coordination) during the screening interview.
FMR1 premutation carriers completed genetic testing to quantify the CGG repeat length,
and a structured neurological evaluation using the International Cooperative Ataxia Rating
Scale (ICARS) [43], conducted by a movement disorder specialist (P.K.). All participants
completed a T2-weighted MRI and an abbreviated battery of the Stanford–Binet Intelligence
Scales, Fifth Edition (SB-5) [44] to quantify cognitive abilities.
FMR1 premutation carriers were classified as FXTAS+ (n = 9), FXTAS− (n = 6), or in-
conclusive (n = 4) based on diagnostic standards [1]. The FXTAS+ group included indi-
viduals meeting the diagnostic standards for definite (n = 1), probable (n = 6), or possible
FXTAS (n = 2). The FXTAS− group included premutation carriers with no radiological
or clinical signs of FXTAS (n = 6). Four premutation carriers who failed to complete the
neurological evaluation due to scheduling issues (n = 3) or the MRI scan due to claus-
trophobia (n = 1) were categorized as inconclusive and were excluded from the analyses
of the FXTAS+, FXTAS−, and control groups (i.e., the first objective of the study). Eight
participants (5 premutation carriers and 3 healthy controls) reported being on medication
within 48 h of testing, including antidepressants (selective serotonin reuptake inhibitors: 2
premutation carriers and 1 control; other antidepressants: 3 premutation carriers), sedatives
or hypnotics (1 premutation carrier), levothyroxine (2 controls), or a mood stabilizer (1
premutation carrier).
2.2. Procedures and Approaches
All procedures involved in this research were approved by the institutional review
board at the UT Southwestern Medical Center and Children’s Hospital of Dallas in accor-
dance with the Declaration of Helsinki. The IRB number is STU 052013-43 with an approval
date of 13 August 2013. Written consent was obtained from each adult individual before
the administration of tests and procedures.
2.2.1. T2-Weighted Magnetic Resonance Imaging (MRI) Scan
All participants completed a T2-weighted MRI scan (repetition time = 6350 ms; echo
time = 100 ms; flip angle = 120◦; field of view = 256 × 156 × 256 mm3; 78 axial slices;
voxel size = 1 mm2 × 2 mm; no gap) to evaluate radiological abnormalities associated
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with FXTAS [1,7,45]. T2-weighted scans were analyzed by a trained radiologist (S.L.) with
expertise in neurological disorders.
2.2.2. CGG Repeat Length
The CGG repeat length was examined for all premutation carriers. Molecular testing
was conducted at Dr. Berry-Kravis’ Molecular Diagnostic Laboratory at Rush University.
Genomic DNA was isolated from peripheral blood leukocyte samples. The FMR1 poly-
merase chain reaction test with quantification of the allele-specific CGG repeat length was
performed using commercially available kits (Asuragen, Inc., Austin, TX, USA).
2.2.3. Neurological Examination
FMR1 premutation carriers completed a structured neurological evaluation, including
the ICARS, administered by a movement disorder specialist with expertise in ataxia (P.K.).
The ICARS is comprised of 19 sections, examining postural and gait disturbances, kinetic
function (i.e., limb ataxia), dysarthria and speech disorders, and oculomotor issues. Higher
scores indicate more severe neuromotor issues [46,47].
2.2.4. Gait Assessment
All sensorimotor assessments were administered on an AMTI AccuGait walkway
(American Mechanical Technology, Inc., Watertown, MA; length: 2.9 m, width: 1.2 m). Prior
to testing, 42 passive reflective markers were attached to major joints, based on an industry
standardized Plug-in-Gait Full Body template (Vicon, Centennial, CO, USA). Kinematic
data were recorded using ten Vicon Vantage V5 cameras and a motion capture system with
a spatial error of 2 mm and a sampling rate of 100 Hz.
A starting and a finishing line were set 2 m away from the entrance and exit of the
AccuGait walkway for a total of 6.9 m of walking distance for each individual. Partici-
pants started each trial by standing upright at the starting line with their feet side-by-side.
After receiving an audio cue, participants began walking continuously toward the finish
line at their preferred speed. All participants completed three trials of non-constrained
walking while barefoot. Practice trials were administered prior to data recording to en-
sure participants felt comfortable wearing the reflective markers and understood task
instructions.
To limit variability in the rates at which individuals increased or decreased their
walking speed at the beginning and end of the walkway, only kinematic data from the
middle of the walkway representing individuals’ preferred speeds were analyzed. The heel
strikes and toe-offs of each leg were manually labeled on the raw kinematic data by a
trained scorer and double-checked by a separate trained scorer (M.T.). Kinematic data were
then exported, filtered, and analyzed using custom scripts in Matlab 2019A (MathWorks,
Inc., Natick, MA, USA). A low-pass fourth order Butterworth filter was applied at a cutoff
frequency of 7 Hz to filter the raw kinematic data.
Consistent with prior studies examining gait impairments across the spatial, temporal,
and kinematic domains in other clinical populations [48,49], dependent gait variables
were derived from the post-processed kinematic time series and separated into these three
categories. The spatial features of the gaits included stride length (anterior–posterior
distance from the point-of-heel strike of one leg to the point-of-heel strike of the same leg)
and step width (lateral distance between the heel markers of the leading and trailing legs
at the heel strike of the leading leg). Temporal features of the gaits included stride duration
(duration between two consecutive heel strikes of the same leg), stride velocity (ratio of
stride length over stride time), percentage of double support time (percent of stride time
spent in the double-limb support phase for the leading leg), and cadence (number of steps
per minute). Kinematic features included the standard deviation of the center of mass
(COM) in the mediolateral direction and the ankle and knee joint angles of the ipsilateral
and contralateral legs at heel strikes and toe-offs. The gait variables of the left and right
leg were pooled to derive each individual’s mean and coefficient of variation (CoV) across
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legs and strides. The CoV was calculated as the standard deviation/mean to provide
information on gait variability while accounting for differences in mean performance.
2.2.5. Upper Limb Assessment
To assess the upper limb movement characteristics of FMR1 premutation carriers,
tests of static and dynamic reaching were administered. Prior to the tests, individuals’
hand apertures were measured to ensure the size of the target boxes was individualized.
Participants were requested to form a C-shaped pose using the right thumb and index
finger (Figure 1A), and the measurement was used as a reference to select from eleven
toy boxes with edge lengths of 1.5, 3.6, 5.0, 5.8, 7.0, 8.4, 9.2, 10.5, 11.4, 12.4, or 13.4 cm.
Boxes with an edge length closest to 1× (small) and 1.5× (large) each individual’s hand
aperture were selected for testing. If an individual’s hand aperture was the mean of two
boxes, the smaller box was selected for testing. Four boxes (range: 3.6–7.0 cm) were used
as the small box target, and seven boxes (range: 5.0–11.4 cm) were used as the large box
target. A reflective marker was attached on top of each toy box to allow the Vicon system
to capture the moving trajectory of the box.
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Figure 1. (A) A participant used her index finger and thumb to form a C-shaped pose to allow her
hand aperture to be determined. The examiner measured the distance (cyan line) between the finger
tips as the length of the participant’s hand aperture. (B) A skeleton figure, depicted in the sagittal
plane to show a representative reaching while standing trial when the participant reached a target
box (cyan circle). The target was set at one arm’s length from the participant in alignment with
the midline of his body to allow him to bend forward to reach and lift the target. (C) A skeleton
figure depicted in the frontal plane to show a representative walking-for-reaching trial prior to the
participant reaching the target box (cyan circle). The participant reached the box with his trunk facing
forward and the right arm slightly extended to the right.
During static trials, participants stood with feet side-by-side at the center of the
walkway and their arms at their sides with fingers loosely closed (Figure 1B). The target
box was set on top of a small tray adjusted to each participant’s hip height. The tray was
positioned at one arm’s length from the participant in alignment with the midline of their
body to allow individuals to bend forward to reach and pick up the target. After receiving
the audio cue, participants reached and lifted the toy box using their right arm at their
preferred speed. During dynamic trials, the tray was set at the midpoint of the walkway
and on the right-hand side (Figure 1C). Participants started each trial by standing upright
at the starting line of the walkway with their arms resting at their side and fingers relaxed.
After receiving the audio cue, they walked on the walkway at their preferred speed to reach
and lift the box from the tray and discontinued walking. The tray was positioned sideways
to allow individuals to complete the trial without making a right turn or walking toward
the right side of the walkway. During the task, participants were able to reach the box
with their trunk facing forward and right arm slightly extended to the right. Participants
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completed three trials of reaching for each box (2: small vs. large) for each task condition
(2: static vs. dynamic). All reaching conditions were administered as blocks, and the order
of task conditions was randomized across individuals.
Upper limb kinematic data were low-pass filtered using a fourth order double pass
Butterworth filter with a cutoff frequency of 7 Hz. Upper limb kinematics were the primary
focus of the reaching tasks and were quantified by deriving the reaching duration, maxi-
mum reaching velocity, acceleration time, and reaching smoothness across the shoulder,
elbow, and hand for both the small and large box conditions. The reaching onset was
manually labeled by a trained scorer and double-checked by a separate trained scorer (Z.W.)
based on the vertical displacement of the right-hand marker in Nexus (Vicon, Centennial,
CO, USA). Reaching offset was defined as the first time point at which the velocity of
the toy box marker exceeded 15% of its maximum in the vertical direction and continued
for 0.2 s (i.e., 20 data points). Reaching duration was defined as the temporal duration
between the reaching onset and offset. The maximum reaching velocity of each joint was
then identified, based on the first derivative of the right shoulder, elbow, and hand markers
from reaching onset to offset, respectively. The acceleration time was calculated for each
joint and was defined as the duration from reaching onset until the maximum reaching
velocity of the joint. To evaluate the smoothness of joint movement, the time-integrated,
normalized, dimensionless squared jerk was derived for each joint based on the following
formula [50,51]:











where MT represents the reaching duration, J(t) is the derivative of the acceleration, and
Vpeak is the peak velocity. The DSJP was calculated for the right shoulder, elbow and hand.
2.3. Statistical Analyses
Statistical analyses were performed using IBM SPSS Statistics for Windows, version
25 (IBM Corp., Armonk, NY, USA). Between group comparisons (controls vs. FXTAS− vs.
FXTAS+) were conducted using separate one-way ANOVAs for each dependent variable.
For non-constrained walking, Bonferroni corrections were applied for three domains of
gait measurements to limit type 1 errors, and the alpha level was adjusted to 0.02 (0.05/3
domains ≈ 0.02). For tests of reaching, the alpha level was set at 0.025 (0.05/2 reaching
tasks = 0.025). Homogeneity of variance of all the gait and reaching variables was inspected
using Levene’s test. Dependent variables which violated the assumption of normality were
inspected and Log10 transformed.
Pearson correlations were conducted to determine relationships between the gait
and reaching variables found to be significantly different between groups and age, full
scale IQ, and CGG repeat lengths across all premutation carriers (i.e., FXTAS+, FXTAS−,
and inconclusive individuals; N = 19). Due to the nominal rating of ICARS subscales
and total score, Spearman’s rank correlation coefficient (rho) tests were used to examine
relationships between the gait variables, the ICARS posture and gait subscale, and the total
scores. Reaching variables were examined in relation to the ICARS kinetic function and the
total scores. All correlations were interpreted as significant if p < 0.05 and |r| > 0.5.
3. Results
3.1. Participant Characteristics
The demographic, genetic, and clinical characteristics for each participant group
(controls vs. FXTAS− vs. FXTAS+) are reported in Table 1, and individual characteristics
are shown in Table 2. Participant groups showed no differences in height, weight, sex,
or full scale IQ, although carriers with FXTAS were significantly older than the healthy
controls.
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Table 1. Demographics and clinical characteristics of healthy controls and premutation carriers with and without fragile
X-associated tremor/ataxia syndrome (FXTAS).
Characteristics Controls (n = 16) FXTAS− (n = 6) FXTAS+ (n = 9) F p
Age (yr) 53.13 (8.41) 57.00 (6.20) 63.33 (8.35) # 4.645 0.018 *
Height (cm) 167.61 (7.77) 167.38 (12.76) 165.14 (5.09) 0.269 0.766
Leg length (cm) 86.31 (7.21) 89.33 (5.78) 85.93 (2.61) 0.686 0.512
Weight (kg) 80.77 (16.41) 82.56 (26.42) 83.77 (25.11) 0.060 0.941
Male (n) ϕ 8 2 3 0.883 0.643
Full scale IQ 106.63 (14.15) 99.50 (8.14) 102.67 (16.73) 0.622 0.544
CGG repeats — 74 (60–102) 83 (58-107) 0.416 0.531
ICARS speech — 0 (0) 0 (0–2) 1.493 0.245
ICARS kinetic — 0 (0) 2 (1–7) † 9.288 0.010 *
ICARS oculomotor — 0.5 (0–1) 0 (0–3) 0.468 0.507
ICARS posture and gait — 1.5 (0–3) 5 (1–7) † 12.039 0.005 **
ICARS total — 2 (0–4) 8 (2–19) † 9.510 0.009 **
Age, height, leg length, and weight are reported as (mean (SD)); CGG repeats and ICARS scores are reported as (median (range)). ϕ Chi-
square statistics. # FXTAS+ group differs from healthy controls. † FXTAS+ group differs from FXTAS− group. * p < 0.05, ** p < 0.01. Bold
highlight significant findings.
3.2. Gait Performance in FXTAS
Figure 2 shows gait outcomes that were significantly different between participant
groups (see Table S1 for descriptive statistics and the ANOVA results of all gait vari-
ables). FXTAS+ premutation carriers showed decreased stride lengths (group main ef-
fect: F2,27 = 5.825, p = 0.008; control−FXTAS+ = 126.49 mm, SE = 38.16 mm), decreased
stride velocities (group main effect: F2,27 = 5.929, p = 0.007; control−FXTAS+ = 240.41 mm,
SE = 70.69 mm), increased percentages of double support time (group main effect:
F2,27 = 4.800, p = 0.016; control−FXTAS+ =−2.35%, SE = 0.775%), and an increased cadence
CoV (group main effect: F2,27 = 5.926, p = 0.007; control−FXTAS+ = −0.0268 steps/min,
SE = 0.0081 steps/min) compared with the healthy controls. They also showed an in-
creased cadence CoV (group main effect: F2,27 = 7.48, p = 0.003; FXTAS−−FXTAS+ =
−0.03465 steps/min, SE = 0.01 steps/min) and COM standard deviation in the mediolat-
eral direction (group main effect: F2,27 = 5.096, p = 0.013; FXTAS−−FXTAS+ = −4.182 mm,
SE = 1.32 mm) compared with the asymptomatic premutation carriers.
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Table 2. Detailed demographic, genetic, and clinical characteristics for each FMR1 gene premutation carrier.
ID Age Sex CGG
ICARS
T2 Scan Neurological Exam Clinical
ClassificationSpeech Kinetic Oculomotor Gait Posture Total
1 55 F 87 0 0 1 1 2 Generalized white matter lesion,cerebral atrophy type 1 Tremor (−) Gait ataxia (−) FXTAS−
2 61 F 102 0 0 1 2 3 Generalized white matter lesion,cerebral atrophy type 2 Tremor (−) Gait ataxia (−) FXTAS−
3 58 M 60 0 0 1 3 4 (−) Tremor (−) Gait ataxia (−) FXTAS−
4 58 M 63 0 0 0 2 2 (−) Tremor (+) Gait ataxia (−) FXTAS−
5 46 F 68 0 0 0 0 0 Mild white matter lesion, whitematter hypersensitivity Tremor (−) Gait ataxia (−) FXTAS−
6 64 F 80 0 0 0 1 1
Mild white matter lesion, white
matter hypersensitivity, cerebral
atrophy type 2
Tremor (−) Gait ataxia (−) FXTAS−
7 54 F 99 0 2 0 5 7 Mild cerebellar features Tremor (+): mild Probable
8 59 F 107 0 1 2 5 8 Probable
9 71 M 85 1 2 2 7 12 Generalized white matter lesion,cerebral atrophy type 3 Tremor (+) Gait ataxia (+) Definite
10 52 F 81 0 1 0 4 5 Cerebral atrophy type 1 Tremor (+) Gait ataxia (+) Probable
11 77 F 75 2 7 3 7 19 Tremor (+) Gait ataxia (+) Probable
12 67 F 62 0 1 0 1 2 Mild white matter lesion, whitematter hypersensitivity Tremor (+) Gait ataxia (−) Possible
13 65 M 58 0 3 0 5 8 (−) Tremor (+) Gait ataxia (+) Probable
14 57 M 93 0 5 0 3 8
Suspected middle cerebellar
peduncle sign, cerebral atrophy
type 1, fourth ventricle widening,
atrophy of cerebellum and
brainstem
Tremor (+) Gait ataxia (−) Possible
15 68 F (−) Tremor (+) Gait ataxia (+) Probable
16 62 F 102 0 0 0 0 0 Inconclusive
17 70 F 90 0 2 2 2 6 Tremor (+) Gait ataxia (−) Inconclusive
18 61 M 64 Inconclusive
19 59 F 78 Mild white matter lesion, whitematter hypersensitivity Inconclusive
(−) entry: no abnormality was identified. No entry: data was not collected.
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3.3. Reaching Performance in FXTAS
The participant groups did not differ on any reaching variables during static reaching
(see Table S2 for descriptive statistics and ANOVA results).
Figure 3 shows the representative displacement, velocity, and jerk time series of the
right shoulder and hand of a 65-year-old FXTAS+ participant and an age-matched healthy
control when they walked to reach the small box. The FXTAS+ participant showed a
prolonged reaching duration, decreased maximum reaching velocity, and more oscillatory
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and jerkier joint movement relative to the control individual. Table 3 shows descriptive
statistics and between-group comparisons of all the reaching variables during dynamic
trials of walking-for-reaching. For the small box condition, carriers with FXTAS+ showed
a decreased maximum reaching velocity (p = 0.001–0.015), prolonged acceleration time
(p = 0.014–0.027), and jerkier movement (p = 0.004–0.015) of the right shoulder, elbow, and
hand relative to the healthy controls. Additionally, FXTAS+ individuals showed jerkier
hand movements compared with the carriers without FXTAS (p = 0.004). Carriers with
FXTAS also showed increased reaching durations, relative to the controls and FXTAS−
premutation carriers, although the group difference was not significant after adjusting
for multiple comparisons (p = 0.029). For the large box condition, carriers with FXTAS+
showed decreased maximum velocities of the right shoulder and elbow (p = 0.001 and
0.019), prolonged acceleration times of all joints (p = 0.001 to 0.002), and jerkier hand
movements (p = 0.008) relative to the healthy controls.
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Hand max velocity (cm/s) 214.64 (45.18) 203.57 (36.57) 163.48 (29.08) # 4.872 0.015 * 
Elbow max velocity (cm/s) 147.50 (14.38) 138.62 (17.49) 115.54 (22.46) # 8.991 0.001 ** 
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Figure 3. Representative kinematic profiles of the shoulder (top) and hand (bottom) of a 65-year-old patient with FXTAS
(dashed orange line) and an age-matched healthy control (solid blue line) when they walked to reach and lift the small box.
The FXTAS patient showed a prolonged reaching duration (left), decreased maximum reaching velocity of the shoulder and
hand (middle, highlighted in a cyan box), and more oscillatory and jerkier joint movement (right) relative to the control
participant. Time series were graphed from the reaching onset to offset. Jerk trajectories are shown in absolute values
(cm/s3).
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Table 3. Reaching outcomes (mean (SD)) during dynamic walking trials for the healthy controls and premutation carriers
with and without FXTAS.
Control (n = 16) FXTAS− (n = 6) FXTAS+ (n = 9) F p
Small box condition
Reaching duration (s) 1.25 (0.33) 1.35 (0.34) 1.67 (0.40) 4.047 0.029
Hand max velocity (cm/s) 214.64 (45.18) 203.57 (36.57) 163.48 (29.08) # 4.872 0.015 *
Elbow max velocity (cm/s) 147.50 (14.38) 138.62 (17.49) 115.54 (22.46) # 8.991 0.001 **
Shoulder max velocity (cm/s) 119.36 (11.69) 114.83 (11.33) 97.03 (19.92) # 6.999 0.003 **
Hand acceleration time (s) ϕ 1.65 (0.32) 1.82 (0.28) 2.33 (0.83) # 4.974 0.014 *
Elbow acceleration time (s) ϕ 1.64 (0.37) 1.79 (0.31) 2.32 (0.88) # 4.381 0.022 *
Shoulder acceleration time (s) ϕ 1.57 (0.36) 1.70 (0.33) 2.26 (0.93) # 4.120 0.027 *
Hand DSJP ϕ 29.88 (10.21) 34.49 (12.42) 54.27 (18.85) † 6.829 0.004 **
Elbow DSJP ϕ 31.20 (14.00) 33.46 (11.76) 56.86 (24.89) # 5.242 0.012 *
Shoulder DSJP ϕ 33.75 (15.44) 35.11 (11.18) 60.22 (26.87) # 4.932 0.015 *
Large box condition
Reaching duration (s) 1.28 (0.33) 1.48 (0.21) 1.63 (0.44) 3.124 0.060
Hand max velocity (cm/s) 208.18 (43.89) 212.05 (43.00) 165.04 (31.73) 3.801 0.035
Elbow max velocity (cm/s) 145.93 (16.63) 138.40 (1.683) 115.83 (19.12) # 8.697 0.001 **
Shoulder max velocity (cm/s) 116.01 (13.71) 117.59 (12.19) 98.92 (17.40) # 4.606 0.019 *
Hand acceleration time (s) 1.68 (0.42) 1.77 (0.27) 2.46 (0.57) † 8.962 0.001 **
Elbow acceleration time (s) 1.72 (0.43) 1.73 (0.28) 2.43 (0.58) † 7.583 0.002 **
Shoulder acceleration time (s) 1.61 (0.42) 1.65 (0.28) 2.37 (0.67) † 7.687 0.002 **
Hand DSJP ϕ 30.25 (9.54) 37.26 (7.51) 51.45 (21.53) # 5.692 0.008 **
Elbow DSJP 32.62 (15.35) 40.17 (9.67) 52.43 (29.28) 2.916 0.071
Shoulder DSJP 35.00 (16.41) 40.66 (7.86) 56.89 (29.19) 3.429 0.044
DSJP = dimensionless squared jerk normalized by peak velocity (unitless). ϕ Log10 transformed variables. # FXTAS+ group differs from
healthy controls. † FXTAS+ group differs from FXTAS− group. * p < 0.025. ** p < 0.01. Bold highlight significant findings.
3.4. Demographic and Clinical Correlations
Increased age was associated with a decreased stride length (Table 4; r = −0.517,
p = 0.028) and increased cadence CoV (r = 0.539, p = 0.021) in premutation carriers but not
the controls. Neither IQ nor CGG repeat length were correlated with any gait measures
in the premutation carriers. An increased IQ was associated with a reduced cadence CoV
(r = −0.694, p = 0.003) and COM standard deviation (r = −0.501, p = 0.048) in the controls.
The ICARS total and posture and gait ratings were correlated with all gait variables in the
premutation carriers.
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Table 4. Correlations between gait features and demographic and clinical characteristics for premutation carriers and controls.
Age IQ CGG Repeats ICARS Posture Gait ICARS Total
FMR1 premutation carriers (n = 19)
Stride length (mm) r = −0.517, p = 0.028 * r = −0.206, p = 0.411 r = −0.225, p = 0.386 rho = −0.689, p = 0.009 ** rho = 0.609, p = 0.027 *
Stride velocity (mm/s) r = −0.286, p = 0.250 r = −0.248, p = 0.321 r = −0.143, p = 0.585 rho = −0.697, p = 0.008 ** rho = −0.575, p = 0.040 *
Pct. double support time (%) r = 0.126, p = 0.619 r = 0.246, p = 0.325 r = 0.288, p = 0.262 rho = 0.667, p = 0.013 * rho = 0.559, p = 0.047 *
Cadence CoV (steps/min) r = 0.539, p = 0.021 * r = 0.306, p = 0.217 r = 0.161, p = 0.538 rho = 0.761, p = 0.003 ** rho = 0.672, p = 0.012 *
Step COM SD (mm) r = 0.179, p = 0.477 r = 0.143, p = 0.595 r = −0.006, p = 0.982 rho = 0.644, p = 0.017 * rho = 0.573, p = 0.041 *
Controls (n = 16)
Stride length (mm) r = 0.145, p = 0.592 r = 0.456, p = 0.076 — — —
Stride velocity (mm/s) r = 0.075, p = 0.783 r = 0.461, p = 0.072 — — —
Pct. double support time (%) r = 0.156, p = 0.565 r = −0.046, p = 0.865 — — —
Cadence CoV (steps/min) r = 0.035, p = 0.897 r = −0.694, p = 0.003 ** — — —
Step COM SD (mm) r = −0.033, p = 0.902 r = −0.501, p = 0.048 * — — —
Pct. double support time = percentage of double support time; Step COM SD = COM standard deviation in the mediolateral direction. * p < 0.05. ** p < 0.01. Bold highlight significant findings.
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Neither IQ nor the CGG repeat length were correlated with any reaching variables in
the premutation carriers (see Table S3 for detailed correlation results of the reaching vari-
ables with age, IQ, and CGG repeat length in the premutation carriers and healthy controls).
Increased age was associated with decreased maximum shoulder velocity in the premu-
tation carriers (r = −0.487, p = 0.035), though this effect did not reach our more stringent
significance cutoffs (i.e., |r| > 0.5). Neither age nor IQ were correlated with any reaching
kinematic variables in the healthy controls. Table 5 shows the correlations of the reaching
variables with the ICARS kinetic function and total scores. For the small box condition,
the ICARS kinetic ratings were associated with decreased maximum reaching velocities
of all joints (p = 0.023–0.044) and jerkier movement of the hand (p = 0.034). The ICARS
total score was associated with decreased maximum reaching velocity (p = 0.000–0.006)
and movement smoothness (p = 0.027–0.033) of all joints, as well as increased shoulder
acceleration time (p = 0.030) in the premutation carriers. For the large box condition, the
ICARS kinetic ratings were associated with increased acceleration time of the right shoulder
and hand (p = 0.010 and 0.028) and decreased maximum reaching velocity of the elbow
and shoulder (p = 0.014 and 0.045), respectively. The ICARS total ratings were associated
with increased shoulder, elbow, and hand acceleration times (p = 0.002–0.049), increased
jerkier movement of the hand (p = 0.019), and decreased maximum reaching velocities of
the shoulder and elbow (p = 0.000 and 0.003) in the premutation carriers.
Table 5. Correlation between reaching and clinical characteristics for the premutation carriers.
ICARS Kinetic ICARS Total
Small box condition
Hand max velocity rho = −0.510, p = 0.044 * rho = −0.651, p = 0.006 **
Elbow max velocity rho = −0.535, p = 0.033 * rho = −0.756, p = 0.001 **
Shoulder max velocity rho = −0.562, p = 0.023 * rho = −0.816, p = 0.000 **
Hand acceleration time rho = 0.244, p = 0.362 rho = 0.417, p = 0.108
Elbow acceleration time rho = 0.253, p = 0.344 rho = 0.400, p = 0.125
Shoulder acceleration time rho = 0.343, p = 0.193 rho = 0.542, p = 0.030 *
Hand DSJP rho = 0.532, p = 0.034 * rho = 0.534, p = 0.033 *
Elbow DSJP rho = 0.476, p = 0.062 rho = 0.551, p = 0.027 *
Shoulder DSJP rho = 0.417, p = 0.108 rho = 0.552, p = 0.027 *
Large box condition
Elbow max velocity rho = −0.599, p = 0.014 * rho = −0.783, p = 0.000 **
Shoulder max velocity rho = −0.507, p=.045 * rho = −0.691, p = 0.003 **
Hand acceleration time rho = 0.547, p= 0.028 * rho = 0.632, p = 0.009 **
Elbow acceleration time rho = 0.454, p = 0.077 rho = 0.499, p = 0.049 *
Shoulder acceleration time rho = 0.624, p = 0.010 ** rho = 0.709, p = 0.002 **
Hand DSJP rho = 0.368, p = 0.161 rho = 0.577, p = 0.019 *
* p < 0.05. ** p < 0.01. Bold highlight significant findings.
4. Discussion
The current work aimed to (1) quantify the locomotor and upper limb kinematics
during tasks of non-constrained walking and reaching in healthy controls and premutation
carriers with and without FXTAS and (2) determine the relationships of gait and reaching
variables with FXTAS symptoms and risk. To our knowledge, this is the first study to
simultaneously examine the gait and upper limb kinematics in FMR1 premutation carriers.
Three key findings are highlighted. First, individuals with FXTAS showed multiple gait
abnormalities compared with both the healthy controls and FXTAS− carriers, suggesting
that assessment of a non-constrained gait could serve as a potential disease-specific behav-
ioral marker to quantify and monitor FXTAS degeneration. Second, carriers with FXTAS
also showed atypical reaching kinematics specific to conditions during which they were
walking, indicating that gait alterations impacted their ability to perform activities of daily
living, including upper limb actions. Third, gait and reaching abnormalities in FXTAS were
associated with more severe clinical motor issues, indicating that quantitative assessments
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of gait and upper limb movement may reliably identify clinically relevant motor decline
associated with FXTAS.
4.1. Gait Atypicalities in FXTAS
We found that individuals with FXTAS showed multiple quantifiable alterations of a
non-constrained gait, including decreased stride length and stride velocity and increased
percentage of double support time and variability of cadence and lateral movement of
the COM. Atypicality of a non-constrained gait is a strong predictor of reduced quality
of life and early mortality in healthy, aging individuals and individuals with neurolog-
ical disorders [52,53]. Decreased gait amplitude and increased gait variability are asso-
ciated with typical aging in healthy controls [54,55] and covary with cognitive ability
(Table 4) [21,56,57]. However, more severe issues, as evident in the current study, in pre-
mutation carriers with FXTAS (Figure 2) appeared to be quantifiable, suggesting that these
measurements may help differentiate disease processes from normative levels of decline in
gait control.
Gait abnormalities, documented here in FXTAS+ individuals, implicate multiple sen-
sorimotor brain regions supporting locomotor activities. The vermis and intermediate zone
of the cerebellum are important sites involved in gait control. Circuits within the cerebellar
vermis and intermediate zone are involved in integrating afferent inputs from central
pattern generators, somatosensory receptors, and the interneurons of the spinocerebellar
tracts to modulate spatial and temporal components of the gait at the periphery [58,59]. The
lateral cerebellar circuits project to several cortical sensorimotor regions via the thalamus,
including the primary motor and premotor cortices and the posterior parietal cortex, to
facilitate the voluntary and adaptive control of walking [60]. Interruption to these cor-
tical cerebellar pathways often results in gait ataxia, characterized by the inconsistent
length, timing, and direction of steps, as well as increased and disoriented trunk or COM
movement. Previous studies have documented reduced cerebellar volume associated
with increased double support times and step widths in male FMR1 premutation carriers
relative to controls, implicating cortical cerebellar degeneration in aging FMR1 premutation
carriers [33]. Gait atypicalities, documented here in individuals with FXTAS, are quite
similar to the impairments observed in cerebellar patients, including prolonged double
support time and increased gait variability [61,62], suggesting that cerebellar disruptions
contribute to gait decline in patients. These behavioral results are also in alignment with the
neuropathology and anatomical MRI studies of patients with FXTAS, showing disrupted
microstructural integrity of the cerebellar peduncles, inclusions in neurons and astrocytes
of the cerebellum and brainstem, and general cerebral atrophy, suggesting that reduced cor-
tical cerebellar modulation of locomotor coordination may serve as a subclinical indicator
detectable prior to disease onset or early in the course of FXTAS degeneration [59,62–65].
We did not identify any differences in joint angular movement amongst the FXTAS+
or FXTAS− individuals relative to the controls. Several factors may account for this non-
significant finding. First, the cortical cerebellar network modulates joint movements in
a synergetic manner, during which a set of joints move with a coordinated timing and
range of movement to achieve the task goal [66]. As such, it is possible that atypicalities of
joint kinematics are reflected at the collective motor chain level, including the spatial and
temporal components of the gait (Figure 2). Additionally, our joint angular measurements
were derived at heel strikes and toe-offs alone, which do not afford quantification of possible
deficits at other time points of a gait cycle in carriers with FXTAS. Furthermore, no FMR1
premutation carriers in our sample reported any neurological concerns during their initial
screening interview. This aspect of our study design allowed us to assess FXTAS during
early or more mild stages, but also suggests that patients’ gait impairments may not have
manifested yet at the joint level. Furthermore, musculoskeletal weakness (e.g., reductions
in deep tendon reflexes and somatosensation) contributing to the control of lower limb
joint movement has been reported primarily in male premutation carriers [1,35–37]. Our
sample consisted of 68.4% female carriers, suggesting that neurodegeneration affecting
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joint movements may be specific to males with FXTAS [17,27]. It is also possible that female
premutation carriers are less vulnerable to developing severe neurological impairments,
including gait atypicalities, reflecting protective effects of the X chromosome [67,68]. Lastly,
due to the heterogeneous presentations of FXTAS, there is a likelihood that not all carriers
with FXTAS present aberrant joint angular movements during walking. Future studies
involving larger cohorts of aging FMR1 premutation carriers are warranted to examine
the sensitivity of gait quantification for characterizing fundamental motor skill deficits
and identifying subgroups of individuals with FXTAS who show predominant features of
gait ataxia.
4.2. Reaching Atypicalities in FXTAS
We examined reaching during both standing and walking conditions to understand
the contributions of previously documented postural [13–15] and gait alterations [17,27] to
functional upper limb activities in FXTAS. Reaching abnormalities in FXTAS, including
decreased maximum reaching velocity, prolonged acceleration time, and jerkier movement
of the right arm, were specific to walking conditions, indicating that gait abnormalities
likely contribute to difficulties executing goal-oriented reaching movements [25]. These
findings indicate that assessment of the gait and gait-supported upper limb kinematics may
be critical to identifying FXTAS and tracking aging processes among premutation carriers.
Target overshooting, increased variability of end point accuracy, and reduced mul-
tijoint coordination are the most prominent upper limb ataxic features in cerebellar pa-
tients [28–31,69]. Our findings of jerkier movement of the reaching joints in aging carriers
with FXTAS (Figure 3 and Table 3) are consistent with upper limb ataxia, implicating the cor-
tical cerebellar circuits involved in planning and executing smooth multijoint movements.
Decreased maximum reaching velocities and prolonged acceleration times in individuals
with FXTAS suggest non-cerebellar mechanisms are also disrupted. This hypothesis is
supported by prior results from studies of manual control showing deficit patterns aligned
with bradykinesia [12,70]. Specifically, we previously documented that aging premutation
carriers showed prolonged reaction times, target undershooting, and reduced rates of initial
force production during precision gripping [12]. Increased reaction times and movement
times have also been documented in FMR1 premutation carriers during standardized clini-
cal assessments of manual dexterity [70]. These results suggest that upper limb atypicalities
in aging individuals with FXTAS are characterized by slowed motor behavior, implicat-
ing the basal ganglia circuits [37,71]. This proposition is also supported by evidence of
dopaminergic cell loss, the existence of Lewy bodies in surviving dopaminergic neurons
in the substantia nigra [37,72,73], increased iron deposition in neuronal and glial cells of
the putamen [74], and pre- and post-synaptic nigrostriatal dysfunction [75] in patients
with FXTAS.
Although reaching kinematics appeared intact in carriers with FXTAS during reaching-
in-standing (Table S2), we would not rule out the possibility that compromised cerebellar
and basal ganglia circuits may still affect upper limb control while standing. For the small
box condition, both the reaching duration (p = 0.032, Cohen’s d = 0.475) and acceleration
time of the shoulder joint (p = 0.045, Cohen’s d = 0.673) showed medium to large effect
sizes. Additionally, the maximum velocity of the elbow (p = 0.051, Cohen’s d = 0.430) and
acceleration time of the elbow (p = 0.051, Cohen’s d = 0.422) and hand (p = 0.051, Cohen’s d
= 0.418) also showed medium effect sizes during the large box condition, suggesting that
FXTAS may involve more subtle or variable reductions in reaching movement speed that
also are present during standing.
4.3. Upper and Lower Limb Kinematics and Their Relation to Demographic and Clinical
Characteristics in FMR1 Premutation Carriers
Consistent with previous studies [17,26,27,33], we found that gait abnormalities in
premutation carriers were strongly correlated with the ICARS posture and gait subscores
and total scores, suggesting that kinematic assessment of non-constrained walking may
reliably identify clinically relevant declines in FXTAS. In contrast, during walking-for-
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reaching trials, the ICARS kinetic subscores did not correlate with the acceleration time or
jerk measures in the premutation carriers. This finding might be accounted for by several
factors. First, it is possible that upper limb movement impairments represent distinct
neurodegenerative mechanisms that are different from degeneration specific to ataxia and
assessed by the ICARS. Second, it is possible that clinical rating scales are less sensitive than
our quantitative approaches for identifying subtle or early indicators of FXTAS, particularly
from a subclinical sample of FMR1 premutation carriers.
Increased age was associated with decreased stride length and increased cadence CoV
in the FMR1 premutation carriers, while age was not associated with any gait measurements
in the healthy controls. This finding demonstrates that premutation carriers may show an
earlier or more rapid decline in gait control relative to healthy aging [3,4,76,77], though it
should be noted that our control group was younger than our FMR1 premutation carriers
(Table 1). We also found that lower IQ was associated with an increased cadence CoV
and COM standard deviation in the healthy controls, but not in the FMR1 premutation
carriers, suggesting that sensorimotor and broader cognitive issues may be independently
affected during aging in premutation carriers. Furthermore, the CGG repeat length was not
associated with any gait or reaching variables in the FMR1 premutation carriers (Table 4
and Table S3). Shichman et al. [70] documented a possible inverted U shape between visual
memory performance and CGG repeat size in FMR1 premutation carriers, postulating
increased rates of memory errors in carriers with mid-length expansions. It is possible that
CGG length and FXTAS symptoms and risk vary in a non-linear fashion. Future studies
involving larger cohorts of aging FMR1 premutation carriers across a broad range of CGG
repeat lengths are warranted to elucidate patterns of potential non-linear relationships and
better understand molecular mechanisms of different sensorimotor issues in FXTAS.
5. Limitations and Future Directions
Our results should be considered in the context of a few limitations. First, the study
consisted of a small cohort of FMR1 premutation carriers that limited our statistical power
and ability to capture variability in clinical and motor presentations among carriers. Fu-
ture studies involving larger cohorts of premutation carriers with and without FXTAS
are needed to examine the sensitivity of gait and reaching variables for characterizing
fundamental motor skill deficits and their variation across individuals and disease stages.
Second, our sample primarily consisted of female premutation carriers. Given that FXTAS
penetrance is reduced in females, our results might be biased against identifying movement
alterations that may be more prominent in male premutation carriers. Third, while report-
ing behavioral findings related to the CGG repeat length is important, other molecular
measurements, including mRNA, methylation ratios, and FMR protein will be important
for clarifying the molecular mechanisms of FXTAS onset, risk, and progression. Lastly,
these tasks were administered in the context of a larger assessment battery. Given the time
constraints and concerns regarding participant fatigue, three trials were administered for
each of the gait and reaching tasks. Although our findings on non-constrained walking
were consistent with previous work [17,26,27,33], future studies shall include more trials to
increase the reliability of the kinematic quantifications for gait and reaching [78].
6. Conclusions
Individuals with FXTAS showed gait alterations relative to healthy controls and
asymptomatic FMR1 premutation carriers. Carriers with FXTAS also showed atypical
upper limb kinematics, presenting features similar to basal ganglia-related bradykinesia
and Parkinsonism. These findings highlight the critical need to develop targeted and
objective measurement strategies to distinguish FXTAS and asymptomatic premutation
carriers, as well as the ataxic and bradykinetic features of FXTAS.
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